Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126357 | 1.00 | KDM1A (0.52) | KDM1AFFAR1HTR2CHTR2BSLC6A2 | |
| SCHEMBL13742600 | 1.00 | KDM1A (0.52) | KDM1AFFAR1HTR2CHTR2BSLC6A2 | |
| SCHEMBL30681455 | 1.00 | KDM1A (0.52) | KDM1AFFAR1HTR2CHTR2BSLC6A2 | |
| SCHEMBL4987635 | 0.86 | KDM1A (0.42) | KDM1AFFAR1HTR2CHTR2BSLC6A2 | |
| SCHEMBL4138468 | 0.84 | KDM1A (0.55) | KDM1AHTR2CHTR2BSLC6A2HTR2A | |
| SCHEMBL4138471 | 0.84 | KDM1A (0.55) | KDM1AHTR2CHTR2BSLC6A2HTR2A | |
| SCHEMBL4986591 | 0.81 | KDM1A (0.41) | KDM1AFFAR1HTR2CHTR2BSLC6A2 | |
| SCHEMBL4982381 | 0.81 | POLB (0.45) | KDM1AHTR2CHTR2BSLC6A2HTR2A | |
| SCHEMBL1817989 | 0.80 | BACE1 (0.61) | KDM1AHTR2CHTR2BSLC6A2HTR2A | |
| SCHEMBL1817991 | 0.80 | BACE1 (0.61) | KDM1AHTR2CHTR2BSLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| WO-2023125846-A1 | COMPOUND FOR PREVENTING AND TREATING CORONAVIRUS INFECTION, CONJUGATE THEREOF AND METHOD THEREFOR | 苏州爱科百发生物医药技术有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-2195293-A2 | CYCLOPTOPYL AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| WO-2009024823-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | KDM1A 17/4885FFAR1 4287/4885HTR2C 4347/4885 |
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | KDM1A 3105/4885FFAR1 43/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.